Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care

Journal of Mental Health Policy and Economics

Volumn 11, Issue 2, 2008, Pages 89-97

  Stargardt, Tom ^a   Weinbrenner, Susanne ^b   Busse, Reinhard ^a   Juckel, Georg ^c   Gericke, Christian A ^d  

^a TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

^b Agency for Quality in Medicine   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; TIAPRIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; FEMALE; GERMANY; HEALTH CARE PLANNING; HEALTH CARE POLICY; HOSPITAL BED UTILIZATION; HOSPITAL COST; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; MOTOR DYSFUNCTION; OUTCOME ASSESSMENT; RISK ASSESSMENT; SCHIZOPHRENIA; SCHOOL CHILD;

ANTIPSYCHOTIC AGENTS; COHORT STUDIES; COST-BENEFIT ANALYSIS; FOLLOW-UP STUDIES; GERMANY; HEALTH CARE COSTS; HEALTH POLICY; HOSPITALIZATION; HUMANS; LENGTH OF STAY; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT READMISSION; SCHIZOPHRENIA;

EID: 45949093383     PISSN: 10914358     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bromet EJ, Fennig S. Epidemiology and natural history of schizophrenia. Biol Psychiatry 1999; 46:871-881.
2. Freedman R. The choice of antipsychotic drugs for schizophrenia. N Engl J Med 2005; 353:1286-1288.
3. National Institute for Clinical Excellence. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. London: National Institute for Clinical Excellence; 2002.
4. World Health Organization. World Health Report 2003. Geneva: WHO; 2003.
5. Csemansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346:16-22.
6. Davis J, Chen N, Glick J. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60:553-564.
7. Zhang PL, Santos JM, Newcomer J, Pelfrey BA, Johnson MC, de Erausquin GA. Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients. Schizophr Res 2004; 71:137-144.
8. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003; 290:2693-2702.
9. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223.
10. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry 2006; 63:1079-1087.
11. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321:1371-1376.
12. Sernyak MJ, Leslie D, Rosenheck R. Use of system-wide outcomes monitoring data to compare the effectiveness of atypical neuroleptic medications. Am J Psychiatry 2003; 160:310-315.
13. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry 1997; 154:457-465.
14. Hamilton SH, Revicki DA, Edgell ET, Genduso LA, Tollefson GD. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Pharmacoeconomics 1999; 15:469-480.
15. Weiden PJ, Ralphs A, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996; 57:53-60.
16. Conley RR, Love RC, Kelly DL, Bartko JJ. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry 1999; 156:863-868.
17. Conley RR, Kelly DL, Love RC, McMahon RP. Rehospitalization risk with second-generation and depot antipsychotics. Ann Clin Psychiatry 2003; 15:23-31.
18. Essock SM, Hargreaves WA, Covell NH, Goethe J. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 1996; 32:683-697.
19. Tiihonen J, Wahlbeck K, Lönnqvist J, Klaukka T, Ioannidis J, Volavka J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006; 333:Epub.
20. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21:419-429.
21. McKee M, Britton A, Black N, McPherson K, Sanderson C, Bain C. Interpreting the evidence: choosing between randomised and non-randomised studies. BMJ 1999; 319:312-315.
22. Morrato E. Elias M, Gericke CA. Using population-based routine data for evidence-based health policy decisions: Lessons from setting and evaluating national health policy in Australia, the UK, and the USA. J Public Health 2007; 29:463-47 1.
23. Kilian R, Angermeyer MC, Becker T. Methodische Grundlagen naturalistischer Beobachtungsstudien zur ökonomischen Evaluation der Neuroleptikabehandlung bei schizophrenen Erkrankungen. Das Gesundheitswesen 2004; 66:180-185,
24. Lyons JS, O'Mahoney MT, Miller SI, Neme J, Kabat J, Miller F. Predicting readmission to the psychiatric hospital in a managed care environment: implications for quality indicators. Am J Psychiatry 1997; 154:337-340.
25. Schwabe U, Paffirath D. Arzneiverordnungsreport 2004. Berlin: Springer; 2004.
26. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of Clozapine's Effectiveness in Schizophrenia: A Sy~tematic Review and Meta- Analysis of Randomized Trials. Am J Psychiatry 1999; 156:990-999.
27. Thieda P, Beard S, Richter A, Kane J. An economic review of compliance with medication therapy in the treatment of schizophrenia. Psychiatr Serv 2003; 54:508-516.
28. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361:1851-89.
29. Essock SM, Hargreaves WA, Dohm F-A, Goethe J, Carver L, Hipshman L. Clozapine eligibility among state hospital patients. Schizzophr Bull 1996; 22:15-25.
30. Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 2004; 184:346-35 1.
31. Rosenheck R, Leslie D, Sindelar J, Miller EA, Lin H, Stroup TS, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006; 163:2080-2089.
32. Davies L, Lewis M, Jones PB, Barnes TRE, Gaughran F, Hayhurst KP, et al. Cost-effectiveness of first v, second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry 2007; 191:14-22.